Last reviewed · How we verify
Primary Immunoglobulin A Nephropathy
Approved treatments
- Pulmicort Respules · AstraZeneca K.K.
- Fabhalta · Novartis
Iptacopan binds to Factor B, regulating C3 cleavage and downstream effects in the alternative complement pathway, controlling IVH and EVH in PNH and inhibiting local activation in IgAN and C3G.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Primary Immunoglobulin A Nephropathy patent landscape — cliff calendar, originator estates, attackable patents
- Primary Immunoglobulin A Nephropathy treatment landscape brief
- Primary Immunoglobulin A Nephropathy treatment updates RSS
Frequently asked questions about Primary Immunoglobulin A Nephropathy
What drugs treat Primary Immunoglobulin A Nephropathy?
Tracked treatments include Pulmicort Respules, Fabhalta.
What is the treatment for Primary Immunoglobulin A Nephropathy?
Standard treatment for Primary Immunoglobulin A Nephropathy includes Pulmicort Respules, Fabhalta. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Primary Immunoglobulin A Nephropathy patent cliff · Primary Immunoglobulin A Nephropathy CI report
- Treatment: Pulmicort Respules · AstraZeneca K.K.
- Treatment: Fabhalta · Novartis
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing